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Abstract 63 
Amyotrophic lateral sclerosis (ALS) primarily affects upper and lower motor neurons. 64 
Phosphorylated TAR DNA-binding protein of 43 kDa (TDP-43) inclusion bodies are 65 
reportedly a pathological hallmark of sporadic ALS. Here, we present an atypical case of 66 
sporadic ALS that progressed very slowly, persisted for 19 years, and clinically appeared to 67 
only affect the lower motor neurons; however, upper motor neuron degeneration was 68 
detected on autopsy. Furthermore, no inclusion bodies positive for phosphorylated TDP-43, 69 
ubiquitin, fused in sarcoma, or SOD1 were detected in the CNS. We performed 70 
exome-sequencing data analysis but found no genetic disorders. This was therefore an 71 
unusual case of lower motor neuron-predominant ALS without TDP-43 pathology or 72 
known gene-disease associations. We also reviewed autopsied ALS cases that progressed 73 
slowly and had no phosphorylated TDP-43 or ubiquitin positive inclusions and present the 74 
clinicopathological features of such cases. Based on these results, there may be a sporadic 75 
ALS subgroup that progresses slowly and shows no accumulation of phosphorylated 76 
TDP-43. 77 
 78 
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Introduction 83 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects upper and 84 
lower motor neurons.1 Recently, phosphorylated TAR DNA-binding protein of 43 kDa 85 
(TDP-43) was identified in intracytoplasmic inclusion bodies of ALS, and the accumulation 86 
of TDP-43 is considered a major feature of sporadic ALS.  87 
 Progressive muscular atrophy (PMA), also referred to as spinal progressive 88 
muscular atrophy,2 progressive spinal muscular atrophy,3 or Aran-Duchenne disease4 is 89 
characterized by isolated signs of lower motor neuron (LMN) dysfunction, loss of anterior 90 
horn cells, and preservation of upper motor neuron (UMN) and corticospinal tracts.1 91 
Phosphorylated TDP-43-immunopositive inclusions were also observed in PMA.5 92 
Therefore, sporadic ALS and PMA are now considered to fall within the same disease 93 
spectrum as examples of TDP-43 proteinopathy.  94 
 Here, we present an autopsy case of sporadic ALS clinically mimicking PMA, 95 
but our case had no evidence of phosphorylated TDP-43-positive inclusion bodies or 96 
known gene disorders. This is an ALS case outside the category of TDP-43 proteinopathy, 97 
and thus provides new insight into the classification of ALS. 98 
 99 
Clinical Summary 100 
A 55-year-old, right-handed Japanese woman developed muscle weakness bilaterally in the 101 
proximal part of her lower extremities. Her body weight had decreased by 3 kg in 5 months. 102 
Subsequently, muscle weakness spread to the upper extremities and distal part of the lower 103 
extremities. By the age of 59 years, the patient was unable to climb the stairs or use 104 
chopsticks or a pen. The patient’s medical history included mild hypertension and a partial 105 
colectomy with spleen cholecystectomy, for colon cancer, performed at the age of 54 106 
years. She had no family history of neurological disease. Additionally, there was no history 107 
of consanguineous marriage. 108 
 A neurological examination at the age of 60 years revealed diffuse muscle 109 
atrophy in the upper and lower extremities and trunk, as well as decreased deep tendon 110 
reflexes in the extremities. There was no cognitive dysfunction, cranial nerve symptoms, 111 
pathological reflex, extrapyramidal symptoms, ataxia, major sensory deficit, or autonomic 112 
dysfunction. Laboratory data were normal, except for serum creatine kinase levels and 113 
serum lactate dehydrogenase levels, which were recorded at 710 IU/ml and 486 U/ml, 114 
respectively. Upper and lower limb motor nerve conduction analysis revealed mildly 115 
reduced compound muscle action potential amplitudes and normal conduction velocities, 116 
with no evidence of conduction block or dispersion. The sensory nerves were normal. 117 
Needle electromyography showed both active and chronic denervation in the cervical and 118 
lumbosacral regions and only chronic denervation in the bulbar region. Brain MRI results 119 
showed mild periventricular white matter ischemic changes. Cervical MRI results revealed 120 
mild spinal canal stenosis at the level of C5/6.  121 
 Because atypical ALS with gene abnormalities was considered in the differential 122 
diagnosis, we performed a genetic analysis of this case. This investigation was approved by 123 
the institutional ethics committee of Hiroshima University. Written informed consent was 124 
obtained from the patient. Genetic studies, including whole-exome sequencing (WES), 125 
demonstrated no pathological variation in the genes currently known to be associated with 126 
ALS or spinal muscular atrophy (SMA). No hexanucleotide repeat expansion was detected 127 
in C9orf72. 128 
 Dyspnea gradually progressed and non-invasive positive pressure ventilation was 129 
initiated at the age of 65 years and used throughout the day at the age of 73 years. On the 130 
other hand, the patient’s sonographic tongue thickness was 46.1 mm [healthy control 44.8 ± 131 
3.0 mm; ALS 41.9 ± 4.0 mm (mean ± SD)6], and she showed no clinical signs of tongue 132 
atrophy. In addition, the patient maintained oral intake and cognitive function almost 133 
throughout the clinical course of the disease. The patient died from respiratory failure at the 134 
age of 74 years, and an autopsy was performed. The clinical diagnosis was PMA. The total 135 
duration of the disease was 19 years.  136 
 137 
Pathological Findings 138 
The autopsy was performed 9.6 hours after death, and the tissues were fixed in 20% 139 
buffered formalin. The left cerebral hemisphere was dissected in the coronal plane. The 140 
right hemisphere above the anterior commissure-posterior commissure (AC-PC) line was 141 
dissected in the sagittal plane for sufficient observation of the precentral gyrus. The right 142 
hemisphere below the AC-PC line was dissected in the axial plane for observation of the 143 
posterior limb of the internal capsule. The brainstem and right cerebellum were dissected in 144 
the axial plane, and the left cerebellum was dissected in the sagittal plane. 145 
Six-micrometer-thick paraffin-embedded sections were stained with HE, KB, and 146 
Gallyas-Braak stains. Furthermore, we performed immunostaining with the primary 147 
antibodies listed in Table 1. 148 
 The brain weight was 1100 g after fixation. Macroscopic examination revealed 149 
selective atrophy of the ventral spinal roots, relative sparing of the dorsal spinal roots, 150 
and atrophy of the anterior horn. In the cerebrum, mild atrophy of the precentral gyrus was 151 
observed (Fig. 1A). In the brainstem, atrophy of the medullary pyramid was observed. The 152 
cerebellum had no remarkable findings. 153 
 Microscopically, the anterior and lateral columns showed a bilateral decrease in 154 
myelin sheath staining compared with the posterior column (Fig. 1B). There was almost 155 
total neuronal loss in the spinal anterior horn at all levels of the spinal cord (Fig. 1C–E), but 156 
relative sparing of the Onufrowicz nuclei and Clarke's column. In the brainstem, slight 157 
left-dominant atrophy of the medullary pyramid was also observed (Fig. 1F). Although 158 
myelin pallor and axonal loss of the pyramid were not obvious, CD68-immunopositive 159 
microglia/macrophages were observed to a higher degree than in other areas. Although the 160 
cranial motor nuclei were relatively spared, mild but definite gliosis was observed at the 161 
hypoglossal, facial, and trigeminal motor nuclei (Fig. 1G–I). Betz giant cells were mildly 162 
reduced and some neuronophagia was observed in the primary motor area of the sagittal 163 
section (Fig. 1J, K). The inferior olive nuclei, medullary reticular formation, substantia 164 
nigra, putamen, and globus pallidus were relatively preserved. No 165 
phosphorylated TDP-43-positive intracytoplasmic inclusion bodies, ubiquitinated 166 
intracytoplasmic inclusion bodies, or Bunina bodies were detected in the CNS. Likewise, 167 
no notable fused in sarcoma (FUS) or SOD1 immunoreactivity was detected in the CNS.  168 
 Small amounts of senile plaques, NFTs, and argyrophilic grains were detected in 169 
restricted regions. These pathological features were consistent with Braak amyloid stage 170 
A,7 Thal phase for amyloid β deposition I,8 Consortium to Establish a Registry for 171 
Alzheimer’s Disease score A,9 Braak NFT stage II,7 Braak AT8 stage II,10 and argyrophilic 172 
grains Saito stage II.11 No α-synuclein pathology was detected.  173 
 174 
Discussion 175 
This report described a very slowly progressing ALS case that clinically appeared to only 176 
affect the LMNs except for the cranial nerve area. Postmortem pathological investigation 177 
was able to reveal mild degeneration in UMN and brainstem motor neuron nuclei as well as 178 
degeneration in anterior horn cells. These pathological findings were consistent with ALS. 179 
Notably, this ALS case showed no intracytoplasmic accumulation of phosphorylated 180 
TDP-43. 181 
 In this case, signs of UMN degeneration were not clinically obvious throughout 182 
the clinical course of the disease. We had difficulty in diagnosing whether this was a case of 183 
ALS or another condition primarily affecting the LMNs. As seen in the present case, severe 184 
LMN degeneration can clinically mask signs of UMN degeneration, which is why most 185 
(84.6%) of patients clinically diagnosed as PMA show both UMN and LMN degeneration 186 
through pathological examination.5 In other reports, pathological examination also revealed 187 
UMN degeneration in 2/2 cases12 and 1/2 cases13 of clinically-diagnosed PMA. 188 
 As a pathological feature of this case, no inclusions immunopositive for 189 
phosphorylated TDP-43 were observed. Immunohistologically, ubiquitinated 190 
intracytoplasmic inclusion bodies are known as a major pathological hallmark of ALS. In 191 
2006, phosphorylated TDP-43 was identified as a component of these ubiquitinated 192 
inclusion bodies in sporadic ALS.14,15 With the exception of some familial ALS, including 193 
cases with SOD1 and FUS mutations,16-18 most ALS shows intracellular aggregation of 194 
phosphorylated TDP-43 as a prominent pathological feature. Subsequent studies showed 195 
that phosphorylated TDP-43 inclusion bodies were also observed in PMA cases.5 However, 196 
our case was atypical in that no inclusion bodies immunopositive for either phosphorylated 197 
TDP-43, SOD1, FUS, or ubiquitin were observed although other pathological findings were 198 
consistent with ALS. Slowly progressive ALS cases without phosphorylated TDP-43 or 199 
ubiquitin positive intracytoplasmic inclusions have been rarely reported.2, 19-21 We reviewed 200 
five cases and compared them with the current case in terms of their clinicopathological 201 
features (Table 2). In general, the median survival time of ALS patients was reported as 20–202 
48 months,22 and long-surviving ALS cases are not common. However, the mean disease 203 
duration from disease onset to death or mechanical ventilation of the cases in Table 2 was 204 
16 years, which is considerably longer than the typical disease duration of sporadic ALS. 205 
These cases showed relatively mild bulbar signs and half of the cases did not show 206 
pyramidal signs. The similarity of these cases suggests the existence of a slowly 207 
progressing sporadic ALS subgroup unrelated to the accumulation of phosphorylated 208 
TDP-43. As a differential diagnosis for our patient, we considered atypical ALS with 209 
genetic mutation or other motor neuron degenerative diseases with genetic mutation. To 210 
support this idea, in a previous study, a survival motor neuron-deficient mouse model 211 
showed no TDP-43 pathology.23 However, our case showed no pathological variation in the 212 
genes currently known to be associated with ALS or SMA. 213 
 As another pathological feature of this case, UMN degeneration was very mild. If 214 
proper pathological examination had not been conducted, the UMN degeneration, 215 
especially in the primary motor area, may not have been detected and a diagnosis of ALS 216 
may not have been possible. In this case, we examined the sagittal section of the precentral 217 
gyrus in the left cerebral hemisphere and the coronal section of the precentral gyrus in the 218 
right cerebral hemisphere. Several instances of neuronophagia were observed in the sagittal 219 
section, but typical neuronophagia was not detected in the coronal section with HE staining; 220 
possibly because the sagittal sections vertically correspond to the precentral gyrus and 221 
enable the observation of a wider area than do coronal sections. Accordingly, sequent 222 
sagittal sections may enable the detection of UMN degeneration with increased sensitivity. 223 
 In conclusion, we report an atypical case of LMN-predominant ALS without 224 
TDP-43 pathology or known gene-disease associations. There may be a sporadic ALS 225 
subgroup that progresses slowly and shows no accumulation of phosphorylated TDP-43. 226 
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Figure Legends: 309 
Figure 1: Mild atrophy of the precentral gyrus in the right hemisphere (A). The bilateral 310 
anterior and lateral column showing decreased KB staining compared with the posterior 311 
columns in the cervical spinal cord (B). Lumbar spinal cord showing almost total neuronal 312 
loss of anterior horn cells (C) and severe gliosis as shown by HE staining (D) and 313 
anti-GFAP antibody immunostaining (E). Atrophy of the medullary pyramid, showing 314 
possible left dominance with KB staining (F). Hypoglossal motor nuclei showing relative 315 
sparing of neurons (G) and mild gliosis, as shown by HE staining (H) and anti-GFAP 316 
antibody immunostaining (I). Neuronophagia in the primary motor area, as shown by HE 317 
staining (J). The CD68-immunopositive microglia/macrophage in the primary motor area 318 
(K). Scale bars: (A) 1 cm, (B, F) 2 mm, (D, E, H–K) 50 µm, (C, G) 200 µm. 319 
Figure 1 A-E
Figure 1 F-K
Table 1 Antibodies used for immunohistochemistry
Primary antibodies Host Dilution Source
phosphorylated TDP-43 (pSer409/410) mouse-monoclonal 1:10000 A gift from M. Hasegawa, Japan
ubiquitin rabbit-polyclonal 1:1000 Dako, Glostrup, Denmark
fused in sarcoma (FUS) rabbit-polyclonal 1:200 Sigma-Aldrich, St Louis, MO, USA
Cu/Zn super oxi de di smut ase-1 ( SOD1)  ( 1G2) mouse-monoclonal 1:2000 MBL, Aichi, Japan
GFAP rabbit-polyclonal 1:10 Dako, Glostrup, Denmark
human macrophage CD68 (PG-M1) mouse-monoclonal 1:100 Dako, Glostrup, Denmark
phosphorylated neurofilament (SMI31) mouse-monoclonal 1:20000 Sternberger Monoclonals Inc., Baltimore, MA, USA
phosphorylated tau (AT8) mouse-monoclonal 1:1000 Innogenetics, Gent, Belgium
human amyloid β 11-28  (12B2) mouse-monoclonal 1:50 IBL, Maebashi, Japan
phosphorylated α-synuclein (pSyn#64) mouse-monoclonal 1:10000 A gift from T. Iwatsubo, Japan
Case No 1 2 3 4 5 6
Reference Tsuchiya et al.19 Honma et al.20 Tsuchiya et al.2 Mochizuki et al.21 Mochizuki et al.21 Current case
Year 1999 1999 2004 2016 2016
Sex F M F M M F
Age at onset (years) 42 49 52 48 55 55
Age at death (years) 61 65 71 76 84 74
Disease duration (years) 19 16 19 28 29 19
Duration from onset to NPPV (years) none none none none* none* 10: sometimes,18: always
Duration from the onset to tracheostomy (years) 15 none none 8 14 none
Duration from the onset to mechanical ventilation
(years) 15 none none
13: sometimes,
25: always 14 none
Initial symptom weakness of the leftlower extremity
weakness of the  right
hand
weakness of the right
upper extremity
weakness of the  right
hand
weakness of the left
hand
weakness of the bilateral
lower extremity
Pyramidal sign - + - + + -
Bulbar sign mild mild mild evident* evident* none
Dementia not described none not described none none none
Cause of Death sudden respiratory arrest respiratory failure sudden respiratory arrest malignant lymphoma sudden death respiratory failure
Brain weight (g) 1230 1410 1130 1190 1030 1100
Loss of Betz cells observed mild observed evident evident mild
Degeneration of pyramidal tract evident mild evident mild mild mild
Loss of motor neuron nuclei in the brainstem slight evident evident moderate moderate mild
Loss of anterior horn cells evident evident evident moderate moderate evident
Ubiquitinated inclusion negative negative negative negative* negative*  negative
TDP-43-positive inclusion not described not described not described negative negative negative
Bunina body negative negative negative negative negative negative
F: female, M: male, NPPV: noninvasive positive-
pressure ventilation




Table 2 Comparison among slowly progressive ALS cases without TDP-43 or ubiquitin positive intracytoplasmic inclusions
